Market Place
Sourcing Support
All News #Library
Others
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer
25 Jan 2024 //
BUSINESSWIRE
Osivax Appoints Dr. Chris Martin to its Board of Directors
23 Feb 2023 //
BUSINESSWIRE
Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials
21 Dec 2022 //
BUSINESSWIRE
Osivax Appoints Vincent Bille as CMO & shows Manufacturing Progress for OVX836
12 Oct 2022 //
BUSINESSWIRE
Osivax Announces Vaccine Data Presentations at Global Influenza Conferences
01 Sep 2022 //
BUSINESSWIRE
Osivax Secures EUR 10M Grant from Bpifrance to Support Development of OVX836
23 Jun 2022 //
BUSINESSWIRE
Osivax Provides Development Update on Lead Influenza Vaccine Candidate OVX836
25 May 2022 //
BUSINESSWIRE
Osivax Collaborates with the NIAID for Broad-Spectrum Influenza Vaccines
17 May 2022 //
BUSINESSWIRE
Osivax Appoints Dr. Michael Watson to Its Board of Directors
14 Apr 2022 //
BUSINESSWIRE
French biotech Osivax nabs funding boost for universal flu, covid vaccine work
09 Jul 2020 //
FIERCE BIOTECH
Osivax Receives Over EUR 30M in Public Funding to Support Development
07 Jul 2020 //
BUSINESSWIRE
Osivax Enters Agreement with U.S. NIH to Test Universal Flu Vaccine Candidate
05 Dec 2019 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.